Bipolar Disorder Drugs Market Analysis 2026

• The increase in the prevalence of bipolar disorder is driving the growth of the bipolar disorder Market.

The market for treatments for bipolar disorder is anticipated to rise in the future due to the rising incidence of the condition. Bipolar disorder is becoming more common due to several risk factors, including drug addiction, excessive levels of stress, and others. People with bipolar disorder frequently experience depression, and the condition typically manifests in their late teens or early 20s. Men and women are equally likely to be afflicted by bipolar illness. Thus, an increase in the number of instances of bipolar conditions and the growing need to treat them successfully would grow the market for bipolar disorder treatment. 
•    For instance, according to the Depression and Bipolar Support Alliance, a US-based non-profit association providing support to patients of depression or bipolar disorder, in 2021, approximately 5.7 million adult Americans which was about 2.6% of the U.S. population were affected by bipolar disorder. The median age of the onset of bipolar disorder is 25 years, and more than two-thirds of people suffering from bipolar disorder had at least one relative with the illness. Therefore, the increase in the prevalence of bipolar disorder is driving the growth of the bipolar disorder therapeutics market. 
Source:(https://www.dbsalliance.org/education/bipolar-disorder/bipolar-disorder-statistics/)

Thus The rising prevalence of bipolar disorder underscores the importance of timely identification and appropriate care. With symptoms impacting daily functioning, effective treatments are essential for managing the condition and improving quality of life.

• Immediate approval of bipolar disorder therapeutics by regulatory authorities drives the bipolar disorder market.

The immediate approval of bipolar disorder therapeutics treatment by regulatory bodies is raising the demand for bipolar disorder therapy. The key market players are concentrating on obtaining product approvals from regulatory authorities, which is expected to drive the bipolar disorder treatment market over the forecast period. This is because they want to treat adults with schizophrenia and use it as an adjuvant therapy to lithium or valproate for the maintenance treatment of bipolar disorder in adults.
•    For instance, in January 2023, Luye Pharma Group, an international pharmaceutical company, announced it had received FDA approval for its Rykindo (risperidone), which is an extended-release injectable suspension administered via intramuscular injection once every two weeks. 
Source:(https://www.luye.cn/lvye_en/view.php?id=2140#:~:text=PRINCETON%2C%20N.J.%2C%20January%2015%2C,risperidone)%20for%20extended%2Drelease%20injectable)

•    In September 2022, Otsuka America Pharmaceutical, Inc. and H. Lundbeck announced that the U.S. FDA had approved their new drug application (NDA) for a 2-month medication for schizophrenia and bipolar disorder I in adults. It is called ‘aripiprazole’.
Source:(https://www.otsuka-us.com/news/otsuka-and-lundbeck-announce-us-fda-acceptance-new-drug-application-aripiprazole-2-month-ready)

Side effects associated with drugs restrain the bipolar disorder market.

The lithium (Li) element utilized to make anti-mania medications has the potential to overdose and cause anorexia. Furthermore, as several investigations have indicated, long-term lithium usage might harm the effects of the hormone vasopressin, which can lead to insipid diabetes. This strategy may also limit how widely available over-the-counter bipolar medications are for treating the disease.
Since the age range in which bipolar illness symptoms often manifest is between 20 and 25 years old, parents frequently ignore this fact. This impairs the efficacy of natural bipolar medications, slows down the lengthy process of treating bipolar diseases, and lowers the drug's market value. Many generic drugs have entered the market over the years, challenging the well-established supply networks of over-the-counter mood stabilizers.
Another significant issue with individuals using these kinds of medicines for bipolar therapy is the possibility of drug addiction. The small number of anticonvulsant medications that are authorized for use as over-the-counter treatments for bipolar illness may potentially be a hindrance to the market's explosive expansion worldwide.
•    For instance, some of the medications including carbamazepine, Divalproex sodium, and Lithium used in the treatment of bipolar disorder have some side effects such as nausea, tremors, sexual problems, impaired memory, muscle weakness, decreased thyroid function, liver and kidney damage, skin reactions, and others. 
Source:( https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5164879/)
Hence side effects associated with bipolar medications pose challenges to treatment accessibility and market expansion. Issues like potential overdosing, hormonal impacts, and addiction risks highlight the need for safer and more widely available treatment options for bipolar disorder.

How did COVID-19 impact the bipolar disorder treatment market

The World Health Organization issued a public health emergency on January 30, 2020, following the spread of the COVID-19 virus epidemic to over 100 nations worldwide in December 2019. The three primary ways that COVID-19 impacted the economy were through its direct effects on drug supply and demand, its disruption of medication delivery systems, and its financial effects on businesses and financial markets. Lockdowns across the nation have caused issues for drug trafficking in several nations, including Egypt, Saudi Arabia, China, India, and the United Arab Emirates. Nonetheless, the global market for bipolar illness treatments was somewhat negatively impacted by the COVID-19 pandemic. 
•    For instance, in September 2021, an article published by the Nations Institute of Health (NIH) titled Implications of the COVID-19 pandemic for people with bipolar disorders: A scoping review’, focused on how the clinical course of bipolar disorder (BD) is affected by social isolation, stifling rules, lifestyle changes, and biological circadian rhythm abnormalities brought on by the COVID-19 pandemic, or infection-related worries. According to several research, persons with bipolar disorder (BD) experienced fewer relapses or symptoms that worsened during the pandemic, or less severe psychiatric symptoms and greater feelings of well-being than they had before the pandemic. Patients with bipolar disorder (BD) showed less psychological discomfort than those with major depressive disorder (MDD). 
Source:(https://pubmed.ncbi.nlm.nih.gov/34517248/)
•    For instance, in December 2020, NeuroRx, Inc., a clinical-stage, small molecule pharmaceutical company, and Big Rock Partners Acquisition Corp., a special purpose acquisition company, entered into an agreement and plan of merger to increase the development of novel therapeutics for the treatment of COVID-19 and Bipolar Depression.
Source:(https://www.sec.gov/Archives/edgar/data/1719406/000165495420013699/brpa_ex991.htm)
 

The development of innovative bipolar disorder treatments represents a significant opportunity for the automotive industry.

To address the needs of a wider customer base, boost sales, and boost income, major firms in the bipolar disorder therapeutics and related industry are creating novel treatments for depressive episodes linked to bipolar I or II disease. Bipolar depression is the most common and severe clinical symptom of bipolar illness. These depressive episodes are associated with a worse prognosis, longer duration, and more recurrences than manic/hypomanic episodes. 
•    For instance, in December 2021, Intra-Cellular Therapies, Inc. (ITCI), a US-based biopharmaceutical company, discovered and develops small molecule drugs for the treatment of neuropsychiatric and neurologic disorders, announced U.S FDA approved ‘CAPLYTA’ medication in treating the depressive episodes associated with bipolar I or II disorder in adults, as monotherapy and as adjunctive therapy with lithium or valproate. 
Source:(https://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-announces-positive-phase-3-topline)

•    For instance, in December 2021, Zydus Cadila, a pharmaceutical company, gets the U.S. Food and Drug Administration (U.S. FDA) approval to market the generic drug Cariprazine capsules, which are used in the treatment of schizophrenia.
Source:(https://zyduslife.com/public/pdf/pressrelease/Press-Release-Zydus-receives-final-approval-and-180-days-shared-exclusivity-from-the-USFDA-for-Cariprazine-Capsules-12-09-22.pdf)

•    For instance, in December 2021, Intra-Cellular Therapies, Inc. announced that the United States Food and Drug Administration (FDA) approved CAPLYTA for the treatment of depressive episodes associated with bipolar I or II disorder in adults, as monotherapy and as adjunctive therapy with lithium or valproate. 
Source:(https://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-announces-us-fda-approval-caplytar)

However Innovative treatments targeting depressive episodes in bipolar disorder are being developed to meet the diverse needs of patients. With depressive episodes posing significant challenges, advancements in treatment aim to improve outcomes and prognosis for individuals with bipolar I or II disorder.